Glucocorticoids in the treatment of severe sepsis and septic shock

Current Opinion in Critical Care

Volumn 11, Issue 5, 2005, Pages 449-453

  Annane, Djillali ^a,b  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Adrenal cortex hormones; Animal studies; Clinical pharmacology; Clinical trials; Sepsis

Indexed keywords

FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; PREDNISOLONE;

ADRENAL INSUFFICIENCY; BLOOD PRESSURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GENE INTERACTION; HUMAN; HYPERGLYCEMIA; IMMUNOMODULATION; META ANALYSIS; MORBIDITY; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; REVIEW; SEPSIS; SEPTIC SHOCK; SUPERINFECTION; SYSTEMATIC REVIEW;

ADRENAL INSUFFICIENCY; ANIMALS; FLUDROCORTISONE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; INTENSIVE CARE UNITS; SEPSIS; SHOCK, SEPTIC;

EID: 26944473627     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000176691.95562.43     Document Type: Review

References (49)

1. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365: 63-78. The authors present a comprehensive review of the current knowledge of septic shock pathophysiology and treatments.
2. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004; 32:1928-1948. These are the updated guidelines for the hemodynamic management of septic shock from a task force of the American College of Critical Care Medicine.
3. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873. The general guidelines on sepsis management from an international consortium are presented.
4. Prigent H, Maxime V, Annane D. Science review: mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids. Crit Care 2004; 8:243-252.
5. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamilly members. Annu Rev Biochem 1994; 63:889-895.
6. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95:2435-2441.
7. Paliogianni F, Raptis A, Ahuja SS, et al. Negative transcriptional regulation of human interleukin-2 gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J Clin Invest 1993; 91:1481-1489.
8. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994; 91:752-756.
9. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin ASJ. Role of transcriptional activation of NF-kB in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283-286.
10. Auphan N, DiDonato JA, Rosette C, et al. Immunossupression by glucocorticoids: inhibition of NF-kB activity through induction of IkB synthesis. Science 1995; 270:286-290.
11. Orchinik M, Matthews L, Gasser PJ. Distinct specificity for corticosteroid binding sites in amphibian cytosol, neuronal membranes, and plasma. Gen Comp Endocrinol 2000; 118:284-301.
12. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998; 41:761-767.
13. Edwardson JA, Bennett GW. Modulation of corticotrophin releasing factor release from hypothalamic synaptosomes. Nature 1974; 251:425-427.
14. Shi LJ, He HY, Liu LA, Wang CA. Rapid nongenomic effect of corticosterone on neuronal nicotinic acetylcholine receptor in PC12 cells. Arch Biochem Biophys 2001; 394:145-150.
15. Orlikowski D, Sharshar T, Castel M, Annane D. Acute effects of a single intravenous bolus of 50-mg hydrocortisone on cardiovascular autonomic modulation in septic shock. Crit Care Med 2003; 31 (suppl):A124.
16. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998; 46:589-597.
17. Bellissant E, Annane D. Effect of hydrocortisone on phenylephrine: mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 2000; 68:293-303.
18. Limbourg FP, Huang Z, Plumier JC, et al. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest 2002; 110:1729-1738.
19. Hafezi-Moghadam A, Simoncini T, Yang E, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002; 8:473-479.
20. Mukaida N, Zachariae CC, Gusella GL, Matsushima K. Dexamethasone inhibits the induction of monocyte chemostatic-activating factor production by IL-1 or tumor necrosis factor. J Immunol 1991; 146:1212-1215.
21. Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995; 377:68-71.
22. Perretti M, Flower RJ. Modulation of IL-1-induced neutrophil migration by dexamethasone and lipocortin 1. J Immunol 1993; 150:992-999.
23. Bailey JM, Makheja AN, Pash J, Verma M. Corticosteroids suppress cyclooxygenase messenger RNA levels and prostanoid synthesis in cultured vascular cells. Biochem Biophys Res Commun 1988; 157:1159-1163.
24. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990; 87:10043-10047.
25. Barber AE, Coyle SM, Marano MA, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993; 150: 1999-2006.
26. Barber AE, Coyle SM, Fischer E, et al. Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings. Surgery 1995; 118:406-410.
27. van der Poll T, Barber AE, Coyle SM, Lowry SF. Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia - a clinical research center study. J Clin Endocrinol Metab 1996; 81:3604-3606.
28. Briegel J, Kellermann W, Forst H, et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The phospholipase A2 study group. Clin Investig 1994; 72:782-787.
29. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of 'low-dose' hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003; 167:512-520.
30. Perez SA, Mahaira LG, Demirtzoglou FJ, et al. A potential role for hydrocortisone in the positive regulation of IL-15-activated NK cell proliferation and survival. Blood. 2005 Mar 8; [Epub ahead of print]. This is an excellent paper demonstrating that corticosteroids positively influenced the immune system by favoring the proliferation of natural killer cells.
31. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.
32. Annane D, Sebille V, Bellissant E. for the Ger-Inf-05 Study Group. Effect of low doses of corticosteroids in septic shock-associated early acute respiratory distress syndrome. Crit Care Med 2005. (in press)
33. Oppert M, Schindler R, Husung C, et al. Low dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med. (in press)
34. Maxime V, Fitting C, Annane D, Cavaillon JM. Corticoids normalize leukocyte production of macrophage migration inhibitory factor in septic shock. J Infect Dis 2005; 191:138-144. This outstanding study demonstrates that in human septic shock, corticosteroids downregulate the sepsis-associated overexpression of late mediators like MIF.
35. Yard AC, Kadowitz PJ. Studies on the mechanism of hydrocortisone potentiation of vasoconstrictor responses to epinephrine in the anesthetized animal. Eur J Pharmacol 1972; 20:1-9.
36. Grunfeld JP, Eloy L. Glucocorticoids modulate vascular reactivity in the rat. Hypertension 1987; 10:608-618.
37. Thiemermann C, Vane JR. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 1990; 182:591-595.
38. Paya D, Gray G, Fleming I, Stoclet JC. Effect of dexamethasone on the onset and persistence of vascular hyporeactivity induced by E. coli lipopolysaccharide in rats. Circ Shock 1993; 41:103-112
39. Steiner A, Vogt E, Locher R, Vetter W. Stimulation of the phosphoinositide signaling system as a possible mechanism for glucocorticoid action in blood pressure control. J Hypertens Suppl 1988; 6:S366-S368.
40. Williamson PM, Kohlhagen JL, Mangos GJ, et al. Acute effects of hydrocortisone on plasma nitrate/nitrite activity and forearm vasodilator responsiveness in normal human subjects. Clin Exp Pharmacol Physiol 2005; 32:162-166. This is an important study demonstrating that the early (within 3 hours) vascular effects of corticosteroids are not mediated through inhibition of the NO pathway.
41. Bhagat K, Collier J, Vallance P. Local venous responses to endotoxin in humans. Circulation 1996; 94:490-497
42. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645-650.
43. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27:723-732.
44. Chawla K, Kupfer Y, Tessler S. Hydrocortisone reverses refractory septic shock. Crit Care Med 1999; 27:A33.
45. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 2004; 329: 480. The authors present a meta-analysis of all randomized trials on corticosteroids for septic shock. This study demonstrated that low dose of corticosteroids improve shock duration and survival in septic shock.
46. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171:242-248. This is the first randomized controlled trial demonstrating clinical benefit from low dose corticosteroids in severe community-acquired pneumonia.
47. McKee JI, Finlay WE. Cortisol replacement in severely stressed patients. Lancet 1983; 1:484.
48. Yildiz O, Doganay M, Aygen B, et al. Physiologic-dose steroid therapy in sepsis. Crit Care 2002; 6:251-259.
49. Annane D, Briegel J, Sprung CL. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:2157-2159.